Shukla SK et al. have pinpointed that STAT3 contributes to the acceleration of malignancy and progression of PCa; thus, the targeted inhibition of STAT3 presents a viable therapeutic approach for managing PCa16. Here, STAT3 is linked to posterior cortical atrophy.